RS63630B1 - Semaglutid u kardiovaskularnim stanjima - Google Patents

Semaglutid u kardiovaskularnim stanjima

Info

Publication number
RS63630B1
RS63630B1 RS20220901A RSP20220901A RS63630B1 RS 63630 B1 RS63630 B1 RS 63630B1 RS 20220901 A RS20220901 A RS 20220901A RS P20220901 A RSP20220901 A RS P20220901A RS 63630 B1 RS63630 B1 RS 63630B1
Authority
RS
Serbia
Prior art keywords
semaglutide
pharmaceutical composition
use according
subject
mace
Prior art date
Application number
RS20220901A
Other languages
English (en)
Serbian (sr)
Inventor
Oluf Kristian Højbjerg Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS63630(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of RS63630B1 publication Critical patent/RS63630B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
RS20220901A 2016-04-28 2017-04-28 Semaglutid u kardiovaskularnim stanjima RS63630B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
EP17721109.1A EP3448416B1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
RS63630B1 true RS63630B1 (sr) 2022-10-31

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220901A RS63630B1 (sr) 2016-04-28 2017-04-28 Semaglutid u kardiovaskularnim stanjima

Country Status (24)

Country Link
US (3) US20190134162A1 (cg-RX-API-DMAC7.html)
EP (1) EP3448416B1 (cg-RX-API-DMAC7.html)
JP (1) JP7221694B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250038818A (cg-RX-API-DMAC7.html)
CN (1) CN109069589B (cg-RX-API-DMAC7.html)
AU (2) AU2017256774B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018072020A2 (cg-RX-API-DMAC7.html)
CA (1) CA3022535A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018003045A1 (cg-RX-API-DMAC7.html)
DK (1) DK3448416T3 (cg-RX-API-DMAC7.html)
ES (1) ES2928007T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221150T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060040T2 (cg-RX-API-DMAC7.html)
IL (1) IL262390B1 (cg-RX-API-DMAC7.html)
MA (1) MA44762A (cg-RX-API-DMAC7.html)
MX (1) MX2018012700A (cg-RX-API-DMAC7.html)
MY (1) MY202967A (cg-RX-API-DMAC7.html)
PH (1) PH12018502274B1 (cg-RX-API-DMAC7.html)
PL (1) PL3448416T3 (cg-RX-API-DMAC7.html)
RS (1) RS63630B1 (cg-RX-API-DMAC7.html)
RU (1) RU2768283C2 (cg-RX-API-DMAC7.html)
SI (1) SI3448416T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017186896A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202507395B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768283C2 (ru) * 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях
TWI847306B (zh) 2017-08-24 2024-07-01 丹麥商諾佛 儂迪克股份有限公司 Ｇｌｐ-１組成物及其用途
HRP20230929T1 (hr) * 2018-10-26 2023-11-24 Novo Nordisk A/S Stabilni pripravci semaglutida i njihova upotreba
ES2994462T3 (en) * 2018-12-21 2025-01-24 Novo Nordisk As Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
AU2023285400A1 (en) * 2022-06-08 2024-12-05 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院（湖北省人民医院） 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN107961377B (zh) * 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
PT2651398T (pt) * 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
JP6126097B2 (ja) * 2011-09-06 2017-05-10 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体
WO2015071355A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
RU2768283C2 (ru) 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях

Also Published As

Publication number Publication date
BR112018072020A2 (pt) 2019-02-12
AU2017256774B2 (en) 2024-07-11
RU2018140900A (ru) 2020-05-28
MA44762A (fr) 2019-03-06
KR102778218B1 (ko) 2025-03-10
JP2019514925A (ja) 2019-06-06
EP3448416A1 (en) 2019-03-06
AU2017256774A1 (en) 2018-11-01
MY202967A (en) 2024-05-31
PH12018502274B1 (en) 2024-02-28
WO2017186896A1 (en) 2017-11-02
MX2018012700A (es) 2019-01-30
KR20180135012A (ko) 2018-12-19
PH12018502274A1 (en) 2019-09-09
CA3022535A1 (en) 2017-11-02
US20250262281A1 (en) 2025-08-21
KR20250038818A (ko) 2025-03-19
RU2768283C2 (ru) 2022-03-23
HUE060040T2 (hu) 2023-01-28
SI3448416T1 (sl) 2022-10-28
CN109069589A (zh) 2018-12-21
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
ZA202507395B (en) 2025-09-25
KR20220147712A (ko) 2022-11-03
CN109069589B (zh) 2022-09-06
JP7221694B2 (ja) 2023-02-14
RU2018140900A3 (cg-RX-API-DMAC7.html) 2020-09-28
PL3448416T3 (pl) 2022-11-07
ES2928007T3 (es) 2022-11-14
ZA202507394B (en) 2025-09-25
IL262390A (en) 2018-12-31
HRP20221150T1 (hr) 2022-11-25
US20250288649A1 (en) 2025-09-18
CL2018003045A1 (es) 2018-12-14
DK3448416T3 (da) 2022-10-03
EP3448416B1 (en) 2022-08-10
AU2024227113A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
US20250288649A1 (en) Semaglutide in Cardiovascular Conditions
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
JP7193455B2 (ja) 心血管状態におけるインスリンデグルデク
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
HK1261741B (en) Semaglutide in cardiovascular conditions
HK1261741A1 (en) Semaglutide in cardiovascular conditions
BR122025010585A2 (pt) Uso de semaglutida para reduzir o risco de um evento cardiovascular adverso maior (mace) em indivíduos com diabetes mellitus tipo 2 e alto risco cardiovascular
WO2017149105A1 (en) Liraglutide in renal conditions
WO2017149109A1 (en) Liraglutide in diabetic foot ulcer
HK1259166B (en) Liraglutide in cardiovascular conditions
HK1259166A1 (en) Liraglutide in cardiovascular conditions